- Press Releases
- Notices
Press Releases To List
-
- Jun.23.2022Management / Finance
- Announcement on Disposal of Treasury Shares as Restricted Stock-based Remuneration
-
- Jun.07.2022R & D
- Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
-
- Jun.07.2022R & D
- Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
-
- May.30.2022R & D
- U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
- May.26.2022R & D
- Two Combination Treatments of Opdivo + Yervoy and Opdivo + Chemotherapy Approved in Japan for First-line Treatment of Unresectable Advanced or Recurrent Esophageal Cancer
Notices To List
-
- Jun.24.2022Corporate
- Voting Results (Extraordinary Report) of the 74th Ordinary General Shareholders’ Meeting
-
- Jun.23.2022Corporate
- Notice to Resolutions Passed at The 74th Ordinary General shareholders’ Meeting
-
- May.26.2022Corporate
- Notice to Convene the 74th Ordinary General Shareholders’ Meeting
-
- Dec.10.2021Corporate
- Notice on renewal of Ono’s Corporate Introduction Movies
-
- Dec.09.2021Others
- Notice regarding Unauthorized Access to Linical-owned Server
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
